ACADIA Pharmaceuticals Inc. (ACAD): Today's Featured Drugs Laggard

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

ACADIA Pharmaceuticals ( ACAD) pushed the Drugs industry lower today making it today's featured Drugs laggard. The industry as a whole closed the day down 1.1%. By the end of trading, ACADIA Pharmaceuticals fell $0.61 (-3.0%) to $19.78 on light volume. Throughout the day, 1,728,648 shares of ACADIA Pharmaceuticals exchanged hands as compared to its average daily volume of 3,315,000 shares. The stock ranged in price between $19.66-$20.80 after having opened the day at $20.29 as compared to the previous trading day's close of $20.39. Other companies within the Drugs industry that declined today were: Opexa Therapeutics ( OPXA), down 51.7%, Mast Therapeutics ( MSTX), down 40.9%, XOMA ( XOMA), down 21.3% and BioScrip ( BIOS), down 18.5%.

ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. ACADIA Pharmaceuticals has a market cap of $1.8 billion and is part of the health care sector. Shares are up 344.7% year to date as of the close of trading on Wednesday. Currently there are 8 analysts that rate ACADIA Pharmaceuticals a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates ACADIA Pharmaceuticals as a sell. Among the areas we feel are negative, one of the most important has been weak operating cash flow.

On the positive front, Gentium SpA ( GENT), up 16.6%, GW Pharmaceuticals PLC ADR ( GWPH), up 13.0%, Inovio Pharmaceuticals ( INO), up 10.4% and Alcobra ( ADHD), up 10.4% , were all gainers within the drugs industry with Allergan ( AGN) being today's featured drugs industry leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Dow Tumbles as Trump Calls Off North Korea Summit

Dow Tumbles as Trump Calls Off North Korea Summit

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Automakers Slump as Trump Tariffs Threaten Both Manufacturers and Consumers

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Jim Cramer: Does Saudi Arabia Think Oil Prices Are Too High?

Stocks Could Easily Crater Into Memorial Day Weekend

Stocks Could Easily Crater Into Memorial Day Weekend

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio

Video: Here Is How Real Estate Investment Trusts Can Boost Your Portfolio